Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome
Open accessThe DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Inflammatory bowel disease (IBD) is a chronic complex inflammatory gut pathological condition, examples of which include Crohn’s disease (CD) and ulcerative colitis (UC), which is associated with significant morbidity. Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD. The gut microbiota acts as a metabolic organ and contributes to human health by performing various physiological functions; deviation in the gut flora composition is involved in various disease pathologies, including IBD. This review aims to summarize the current knowledge of gut microbiota alteration in IBD and how this contributes to intestinal inflammation, as well as explore the potential role of gut microbiota-based treatment approaches for the prevention and treatment of IBD. The current literature has clearly demonstrated a perturbation of the gut microbiota in IBD patients and mice colitis models, but a clear causal link of cause and effect has not yet been presented. In addition, gut microbiota-based therapeutic approaches have also shown good evidence of their effects in the amelioration of colitis in animal models (mice) and IBD patients, which indicates that gut flora might be a new promising therapeutic target for the treatment of IBD. However, insufficient data and confusing results from previous studies have led to a failure to define a core microbiome associated with IBD and the hidden mechanism of pathogenesis, which suggests that well-designed randomized control trials and mouse models are required for further research. In addition, a better understanding of this ecosystem will also determine the role of prebiotics and probiotics as therapeutic agents in the management of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in sex hormones levels may lead to microbial dysbiosis which has been previously implicated in IBD and its symptom severity.(40)”
From Association Between Sex Hormone Levels and Gut Microbiota Composition and Diversity—A Systematic Review (2022) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624 · cited 3×
“25% (fewer) of the mucosal microbial genes of healthy individuals [25].”
BackgroundInfluentialChanges of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087 · cited 1×
“The highest incidence rate has been recorded in developed countries, such as North America, Europe, Australia, and New Zealand [6], while recently, IBD has been gradually becoming more common in developing areas such as Asia and South America, and in developing countries such as including Brazil, South Korea, and Chin…”
BackgroundAssociation of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591 · cited 2×
“The NOD2 (nucleotide-binding oligomerization domain containing protein 2), a first gene locus, has been reported as a risk locus for Crohn’s disease (CD) [175,176].”
BackgroundDe Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J. B., Massart, S., Collini, S., Pieraccini, G., & Lionetti, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005963107 · Cited by 5,579 · cited 1×
“Human Bacteroidetes Firmicutes, Enterobacteriaceae Decrease Increase [163]”
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030 · cited 1×
“The NOD2 (nucleotide-binding oligomerization domain containing protein 2), a first gene locus, has been reported as a risk locus for Crohn’s disease (CD) [175,176].”
BackgroundDiarrheagenic Escherichia coli
Nataro, J. P., & Kaper, J. B. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.1.142 · Cited by 5,006 · cited 1×
“Many studies in human IBD patients have reported the commensal bacteria association with the patient’s intestines; for example, an association of adherent/invasive Escherichia coli (AIEC), a normal gut flora of the Enterobacteriaceae group, has been found with CD [121].”
BackgroundMetabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838 · cited 1×
“In addition, certain symbiotic gut microbiota members have been reported to have distinct and specific effects on the host immune system, and are considered key to immune homeostasis [31,37,38].”
BackgroundHost–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722 · cited 1×
“Genome-wide association studies (GWAS) have identified more than 160 genetic loci associated with conferring protection from IBD or increased risk to IBD development [172].”
BackgroundRichness of human gut microbiome correlates with metabolic markers
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013) · Nature · doi:10.1038/nature12506 · Cited by 4,662
Research works printed but not linked: 2
- Zhang, 2007, Wumei pill decoction in the treatment of 72 cases of chronic nonspecific ulcerative colitis, Mod. J. Integr. Tradit. West. Med., 16, 5156
- Yan, 2013, Effect of Astragalus Polysaccharides on Th17/Treg Cytokines and Pulmonary Inflammation in Asthmatic Rats, Chin. Pharmacol. Bull., 29, 1275
Cited by
Items 501–600 of 804
Sahu, M., Kaushik, A., Mishra, A. U., Rout, P. K., Sundaresan, V., Shanker, K., Mani, D. N., & Shukla, A. K. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157538 · Cited by 7
Gupta, P., Debnath, B., Ashique, S., Ramzan, M., Yasmin, S., Shorog, E., Mantry, S., Tariq, M., Sridhar, S. B., Panigrahy, U. P., et al. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-02005-4 · Cited by 7
“Studies has shown that the Peptococcaceae are connected to intestinal inflammation, despite being under-studied in IBD.”
InfluentialCharacterization and optimization of variability in a human colonic epithelium culture model
Pike, C. M., Zwarycz, B., McQueen, B., Castillo, M., Barron, C., Morowitz, J. M., Levi, J. A., Phadke, D. P., Balik-Meisner, M. R., Mav, D., et al. (2024) · ALTEX · doi:10.14573/altex.2309221 · Cited by 12
Song, C., & Zhao, C. (2024) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2408.08026 · Cited by 6
“Research has identified enzymes that facilitate drug transformation through genetic screens and enzymatic analysis [44].”
Zheng, Q., Li, C., Yang, L., & Qiu, Y. (2025) · Current Research in Food Science · doi:10.1016/j.crfs.2025.101061 · Cited by 7
“In IBD, including CD, the gut microbiome is thought to be dysregulated, contributing to the chronic inflammation seen in the disease (Khan et al., 2019; Zheng et al., 2022).”
Merino, J. J., Rey, N. B., & García, R. F. (2025) · Life · doi:10.3390/life15091412 · Cited by 6
“In fact, antibiotics alter the composition of bacteria in the intestinal lumen, indirectly reducing beneficial effects or hindering disease remission [80].”
From Gut Inflammation to Cardiovascular Conflagration: Mapping IBD’s Cardiometabolic Risks
Noble, O., Jeon, D., Lewis, M., Fan, C., Nasir, K., & Abraham, B. P. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01329-4 · Cited by 6
“The micro-biome alterations in patients with IBD are characterized by decreased microbial diversity, stability, and composition, which trigger inflammation both locally and systemically, worsening disease progression [36–38].”
Ткачева, О. Н., Klimenko, N. S., Kashtanova, D. A., Tyakht, A., Maytesyan, L., Akopyan, A. A., Игоревич, К. С., & Strazhesko, I. D. (2023) · Microorganisms · doi:10.3390/microorganisms11041036 · Cited by 7
Vincenzi, A., Goettert, M. I., & de Souza, C. F. V. (2023) · Journal of Applied Microbiology · doi:10.1093/jambio/lxad168 · Cited by 6
Microbiome depiction through user-adapted bioinformatic pipelines and parameters
Nayman, E. I., Schwartz, B. A., Polanco, F. C., Firek, A. K., Gumabong, A. C., Hofstee, N. J., Narasimhan, G., Cickovski, T., & Mathee, K. (2023) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001756 · Cited by 6
Nutraceuticals and biotics in pediatric gastrointestinal disorders
Corsello, A., Scatigno, L., Fiore, G., Baresi, S., Eletti, F., Zuccotti, G., Strisciuglio, C., Dilillo, D., & Verduci, E. (2023) · European Journal of Clinical Nutrition · doi:10.1038/s41430-023-01362-z · Cited by 8
Zhong, Q., Reyes-Jurado, F., & Calumba, K. F. (2023) · Soft Matter · doi:10.1039/d3sm00866e · Cited by 6
Ghehsareh, M. M., Asri, N., Gholam-Mostafaei, F. S., Houri, H., Forouzesh, F., Ahmadipour, S., Sherafat, S. J., Rostami‐Nejad, M., Mansueto, P., & Seidita, A. (2024) · Tissue Barriers · doi:10.1080/21688370.2024.2347766 · Cited by 6
Early subclinical stages of the inflammatory bowel diseases: insights from human and animal studies
Kelly, C., Sartor, R. B., & Rawls, J. F. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00252.2024 · Cited by 6
Gut Microbial Targets in Inflammatory Bowel Disease: Current Position and Future Developments
Sivakumar, N., Krishnamoorthy, A., Ryali, H., & Arasaradnam, R. P. (2025) · Biomedicines · doi:10.3390/biomedicines13030716 · Cited by 7
“In humans with IBD, the low bacterial metabolite levels in faeces suggest that reduced Trp metabolism may be implicated in the aetiology of IBD [11].”
Muthumula, C. M. R., Yanamadala, Y., Gokulan, K., Karn, K., CUNNY, H. C., Sutherland, V. L., Santos, J. H., & Khare, S. (2025) · Experimental Biology and Medicine · doi:10.3389/ebm.2025.10468 · Cited by 6
The interplay between the microbiome and colonic immune system in checkpoint inhibitor therapy
Dehinsilu, J., Sergaki, C., Amos, G. C. A., Fontana, V., & Pirmohamed, M. (2023) · Frontiers in Microbiomes · doi:10.3389/frmbi.2023.1061193 · Cited by 6
“Interestingly however, Chaput et al. show an association between F. prausnitzzi (and other Firmicutes) and an increase in the occurrence of irAE colitis following anti-CTLA-4 treatment (Chaput et al., 2017; Khan et al., 2019).”
BackgroundTang, Q., Xie, J., Jiang, X., Wang, M., Guo, W. Y., Chen, L., Jiang, X., & Li, Q. (2024) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2024.105625 · Cited by 6
Dhar, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.831193 · Cited by 7
“Cytokines release post microglia activation have been found to have a role in behavioral phenotype in stress models (Kreisel et al., 2014).”
BackgroundTomczyk‐Warunek, A., Blicharski, T., Muszyński, S., Tomaszewska, E., Dobrowolski, P., Blicharski, R., Jarecki, J., Arczewska-Włosek, A., Świątkiewicz, S., & Józefiak, D. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010205 · Cited by 7
Citrus sinensis (Sweet Oranges) Wastes: The Orange Wealth
Yousof, S. M., Atta, R., Khalil, I. A. H., Zayed, M. A., & Seddek, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-84436-3_10 · Cited by 6
Smart hydrogel structure for microbiome sampling in gastrointestinal tract
Yoon, D., Park, S., & Park, S. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.133910 · Cited by 6
Cenni, S., Colucci, A., Salomone, S., Pacella, D., Casertano, M., Buono, P., Massimo, M., Miele, E., Staiano, A., & Strisciuglio, C. (2025) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70005 · Cited by 5
Bitter Taste Receptors 38 and 46 Regulate Intestinal Peristalsis
Camillo, L., Pollastro, F., Talmon, M., & Fresu, L. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052092 · Cited by 5
Chen, W., Lin, X., Wang, L., Shan, Y., Li, Y., & Zhu, J. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1541289 · Cited by 5
Yang, Y. J., Kim, M. J., Heo, J. W., Choi, H. N., Lee, D., Kim, Y., & Park, K. (2025) · Molecular & Cellular Toxicology · doi:10.1007/s13273-025-00531-4 · Cited by 6
“In addition, although the exact mechanism causing TJ barrier damage remains unknown, an imbalance of gut microbiota is considered a major factor in the literature (Do et al. 2018; Khan et al. 2019).”
Assessing the effects of tofacitinib on the gut microbiome in inflammatory bowel disease
Favaron, A., Sangfuang, N., McCoubrey, L. E., Awad, A., Ghyselinck, J., Marzorati, M., Verstrepen, L., Munck, J. D., Medts, J. D., Basit, A. W., et al. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107365 · Cited by 5
“Firstly, the composition and metabolic activity of the gut microbiota in IBD patients is characterised by great interindividual variability (Khan et al., 2019; Franzosa et al., 2019; Lavelle and Sokol, 2020).”
Olovo, C. V., Ji, Y., Ocansey, D. K. W., Huang, X., & Xu, M. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116058 · Cited by 5
Kumar, G., Yadav, S., Dwivedi, S., Sharma, A., & Kosey, S. (2026) · Gastroenterology & Endoscopy · doi:10.1016/j.gande.2026.02.001 · Cited by 6
Ghazanfar, H., Kandhi, S., Acherjee, T., Qureshi, Z. A., Shaban, M., Yordanka, D. S., Cordero, D., Chinta, S., Jyala, A., & Patel, H. K. (2023) · Cureus · doi:10.7759/cureus.51004 · Cited by 7
Shagaleeva, O. Y., Kashatnikova, D. A., Kardonsky, D. A., Danilova, E. Y., Ivanov, V. A., Evsiev, S. S., Zubkov, E. A., Abramova, O. V., Zorkina, Y., Morozova, A. Y., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063295 · Cited by 6
“Bacterial population shifts are usually observed in IBD and contribute to changes in metabolite levels [25].”
BackgroundRelevance of Indian Traditional Herbal Brews for Gut Microbiota Balance
Joshi, D. D., Deb, L., Kaul, K., Somkuwar, B. G., Rana, V. S., & Singh, R. (2024) · Indian Journal of Microbiology · doi:10.1007/s12088-024-01251-4 · Cited by 5
“An invasion of the balanced microbiome by the overgrowth of one or more microbial colonies influences the body’s immunity resulting in many gastrointestinal diseases including irritable bowel syndrome (IBD), and inflammatory bowel disorder (IBS) [24].”
Minawala, R., & Faye, A. S. (2024) · Advances in Geriatric Medicine and Research · doi:10.20900/agmr20240003 · Cited by 7
“Thus, with an increase in bacterial species that disrupt the intestinal barrier, there is a shift towards a pro-inflammatory state, which leads to muscle breakdown and impairment [50,51].”
BackgroundJiang, Y., liu, R., Tang, J. H., Li, M., Zhang, D., Pei, Z., Fan, S., Xu, R., Huang, H., & Lin, J. (2024) · Phytotherapy Research · doi:10.1002/ptr.8218 · Cited by 6
“…eventually lead to changes in intestinal flora related functions, including but not limited to changes in fermentation products such as carbohydrates, vitamins, and SCFA, as well as immune imbalance, which is considered to be one of the possible causes of intestinal diseases (I. Khan et al., 2019).”
Aly, R. M., Abohashem, R. S., Ahmed, H. H., & Halim, A. S. A. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01532-w · Cited by 5
Bellach, L., Kautzky‐Willer, A., Heneis, K., Leutner, M., & Kautzky, A. (2024) · Nutrients · doi:10.3390/nu16162584 · Cited by 6
“However, the data on CR and gut microbiome is yet heterogenous with one study pointing towards an increase in α -diversity [23] while another noted a reduction of bacterial abundance and an increase in Clostridium difficile [24], similar to findings in inflammatory bowel disease [25].”
ResultChen, M., Zhou, H., Shen, J., Wei, M., Chen, Z.-Y., Chen, X., Fan, H., Zhang, J., & Zhu, J. (2024) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2024.08.003 · Cited by 5
Pan, J., Peng, K., Ruan, R. R., Liu, Y., & Cui, X. (2025) · Foods · doi:10.3390/foods14050785 · Cited by 6
“Inflammatory bowel disease (IBD) is a chronic inflammatory condition affecting the gastrointestinal tract, characterized by mucosal structural damage, intestinal microbial imbalance, and systemic biochemical abnormalities [12].”
The Inflammatory Processes Driven by Gut Microbiota
Buruş, A., Çeltikçi, B., & Aksoy, Y. (2021) · Acta Medica · doi:10.32552/2021.actamedica.548 · Cited by 6
“However, it is still unclear whether microbiota alterations in IBD are the cause or the result [58].”
BackgroundCannabis and Its Potential Protective Role Against Inflammatory Bowel Disease: A Scoping Review
Nso, N., Nyabera, A., Nassar, M., Alshamam, M. S., Sumbly, V., Vest, M., Patel, N. H., Ojong, G., & Rizzo, V. (2021) · Cureus · doi:10.7759/cureus.18841 · Cited by 7
The Role of the Human Gutome on Chronic Disease
Hoefer, C. C., Hollon, L. K., & Campbell, J. A. (2022) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2022.09.015 · Cited by 5
Qu, D., Gu, Z., Feng, S., Yu, L., Tian, F., Zhang, H., Chen, W., & Zhai, Q. (2023) · Food Science and Human Wellness · doi:10.26599/fshw.2022.9250100 · Cited by 5
Raman spectroscopic molecular fingerprinting of biomarkers for inflammatory bowel disease
Buchan, E., Rickard, J. J. S., & Oppenheimer, P. G. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1345 · Cited by 5
Autophagic cell death in viral infection: Do TAM receptors play a role?
Datan, E., & Salman, S. (2020) · International review of cytology · doi:10.1016/bs.ircmb.2020.10.001 · Cited by 5
Kushkevych, I. V., & Jampílek, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823733-5.00016-7 · Cited by 6
Xu, Z., Mi, S., Chitrakar, B., Wang, L., Li, Y., Shi, R., Sang, Y., Yu, W., & Wang, X. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1698231 · Cited by 4
Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy
Collins, K., Kamath, S., Davis, R. H., Costello, S. P., Bryant, R. V., Day, A. S., & Joyce, P. M. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70826 · Cited by 4
“Maintaining homeostasis between proinflammatory T helper cells (Th1, Th2, Th17) and anti-inflammatory regulatory T cells (Treg) is vital for intestinal health, and this equilibrium is heavily influenced by the gut microbiome [43, 44].”
Guan, W., Xu, D., Yang, S., Zhao, Y., Xie, Y., Lin, M., Liu, Y., Zheng, Y., & Li, J. (2023) · Decoding Infection and Transmission · doi:10.1016/j.dcit.2023.100004 · Cited by 5
Zhang, L., Yao, C., Wang, Q., Shan, C., Zhang, K., Guo, Y., Li, Q. Y., Liu, Z., Liu, P., Geng, S., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202400287r · Cited by 4
“49,50 Consistent with these findings, DRF reduced the diversity of the gut microbiota and relative abundance of Lactobacilli and increased the Bacteroidetes to Firmicutes ratio and relative abundance of Actinobacteria and Proteobacteria .”
Parker, W., Jirků‐Pomajbíková, K., Patel, E. M., Williamson, L. L., Anderson, L. G., & Laman, J. D. (2024) · The Yale Journal of Biology and Medicine · doi:10.59249/vunf1315 · Cited by 4
“Further, alterations in the gut microbiota are often associated with chronic inflam - matory disease, although specific community profiles associated with specific chronic inflammatory conditions are often difficult to identify, and causal relationships are not established [20-22].”
BackgroundRyu, H.-M., Islam, S. M. S., Riaz, B., Sayeed, H. M., Choi, B., & Sohn, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168571 · Cited by 6
“Previous studies have shown increases in specific bacterial groups in models of IBD and colitis, including Clostridiaceae , Erysipelotrichaceae , Peptostreptococcaceae , Staphylococcaceae , and Sutterellaceae [20,92–96].”
BackgroundResultTamimi, T., Abu-Farsakh, N., AlRyalat, S. A., Obeidat, K., Ali, S. D., Hameed, H., Aldabbagh, S., Quzli, A. A., AlSamhori, J. F., Sneineh, A. T. A., et al. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003067 · Cited by 4
Cao, X., Sun, Y., Liu, H., Bi, D., Li, Z., Ding, T., Chen, L., Liu, W., Dong, S., Wei, Q., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07095-w · Cited by 4
“Numerous studies have shown that the gut microbiota plays a prior role in the pathogenesis of IBD [8].”
Masi, L., Ciuffini, C., Petito, V., Pisani, L. F., Lopetuso, L. R., Graziani, C., Pugliese, D., Laterza, L., Puca, P., Vincenzo, F. D., et al. (2022) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2022.1022530 · Cited by 4
Shehri, D. A., Saadah, O. I., Mosli, M. H., Edris, S., Alatawy, M., Alatawi, H. A., Al-Amrah, H., Alatwi, I., Al-Hindi, R. R., & Bahieldin, A. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101415 · Cited by 5
The role of the fecal microbiota in inflammatory bowel disease
Khalaf, R., Sciberras, M., & Ellul, P. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002818 · Cited by 5
“This is impaired in IBD as the mucosal barrier becomes leaky due to the alteration of epithelial tight junctions, apoptosis, and ulceration of the intestinal lining, thus, enabling pathobiont invasion [2,45–48].”
Hajheidari, N., Lorigooini, Z., Mohseni, R., & Amini-Khoei, H. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03416-w · Cited by 4
“Inflammatory bowel disease (IBD) is a chronic and relapsing gastrointestinal disorder that manifests primarily in two forms: Crohn’s disease (CD) and ulcerative colitis (UC) (Khan et al. 2019).”
Outcomes of surgery for inflammatory bowel disease among patients with psychiatric disorders
Ng, A. P., Porter, G. M., Vadlakonda, A., Chervu, N. L., Khan, A., Benharash, P., & Lee, H. R. (2024) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2024.09.025 · Cited by 4
Self-citationHaro-Reyes, J. A., Raghupathi, J. K., & Reddivari, L. (2024) · Nutrients · doi:10.3390/nu16234232 · Cited by 4
Homolak, J., Nikolić, M., Potoč, D., Živković, M., Bakula, D., Budimir, I., Pavić, I., Hrabar, D., Ljubičić, N., & Vražić, D. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01876-5 · Cited by 4
“Microbiota, an important player in IBD [16] is modulated by H.”
BackgroundKim, K., Song, J., Yang, S.-J., Choi, J.-W., Sohn, J., Han, S., Shin, Y.-J., Lee, D.-Y., Lee, S., & Kim, D. (2021) · Journal of Medicinal Food · doi:10.1089/jmf.2021.k.0103 · Cited by 4
Intestinal viral infections of nSARS‐CoV2 in the Indian community: Risk of virus spread in India
Maan, H. S., Chaurasia, D., Kapoor, G. T., Dave, L., Siddiqui, A., Pal, S., Singh, H. O., Biswas, D., & Chowdhary, R. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27480 · Cited by 4
Tong, G., Qian, H., Li, D., Li, J., Chen, J., & Li, X. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264194 · Cited by 5
Marsh, D. T., & Smid, S. D. (2022) · Food & Function · doi:10.1039/d2fo02458f · Cited by 4
Dosh, L., Rappa, F., Jurjus, A. R., Karam, G., Lezeik, R., Masri, J. E., Bucchieri, F., Leone, A., & Jurjus, R. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16010130 · Cited by 4
“…have documented that IBDs are the result of a plethora of interactions of genetic and non-genetic parameters involving the microbiome, the environment, and the immune system, which plays a crucial role in initiating an excessive inflammatory response in genetically susceptible individuals [3,4].”
BackgroundRithi, A. T., Banerjee, A., Mitra, A., Nethaji, K., Ilanchoorian, D., & Radhakrishnan, A. (2024) · Groundwater for Sustainable Development · doi:10.1016/j.gsd.2024.101187 · Cited by 6
MICROBIOTA-GUT-BRAIN SIGNALING: A MINIREVIEW
Kubelková, K., & Macela, A. (2020) · Military Medical Science Letters · doi:10.31482/mmsl.2020.002 · Cited by 4
Østergaard, S. K., Cetin, Z., Rasmussen, H. H., Lærke, H. N., Holst, M., Lauridsen, C., & Nielsen, J. L. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1502967 · Cited by 3
Goyal, M. K., Berinstein, E. M., Dutta, P., Ahuja, V., Higgins, P., Berinstein, J. A., & Bishu, S. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01811-6 · Cited by 4
“Nonetheless, IBD is best understood as the consequence of dysregulated immune responses to dysbiotic gut microbiota, collectively leading to unchecked tissue injury [7, 8].”
Role of ETS2 gene in inflammatory bowel disease: A narrative review
Aakash, F., Kumar, S., Kumari, A., Shweta, F., Rumela, F. N. U., Partab, F., Singla, S., & Perveen, A. (2025) · Medicine · doi:10.1097/md.0000000000044234 · Cited by 3
“[3] Over the years, the incidence of IBD has been increasing globally, particularly in industrialized nations, emphasizing the need for a deeper understanding of its underlying mechanisms to improve treatment strategies.”
Shaw, N., Abbott, R. A., & Pettinger, C. (2025) · Women s Health · doi:10.1177/17455057251387470 · Cited by 4
“Similarly, review findings revealed that many studies did not use a validated tool to assess GI symptoms, with nine studies not reporting the measure used and 47 studies developing a study-specific tool.”
Integrating gut microbiome and host transcriptomics for the personalized management of IBD
Barry, D., Thachuk, C., & Trink, J. (2025) · Epigenomics · doi:10.1080/17501911.2025.2591594 · Cited by 3
Vaghela, P., Dave, B. P., Dabhade, A., Deshmukh, R., Prajapati, B. G., Alsaidan, O. A., Patel, S., Mehta, A., Singh, A., & Dudhat, K. R. (2026) · Antonie van Leeuwenhoek · doi:10.1007/s10482-026-02254-5 · Cited by 3
“Patients with IBD often exhibit a distinct microbial signature marked by reduced diversity of commensal bacteria, including members of the Firmicutes and Bacteroides phyla, and an overrepresentation of pro-inflammatory taxa such as Enterobacteriaceae (Khan et al. 2019).”
Xu, X., Ji, R., Huang, H., Xiao, J., Zhang, H., Kuang, H., & Wang, Z. (2026) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2026.125248 · Cited by 5
Smid, S. D. (2026) · Food & Function · doi:10.1039/d5fo05231a · Cited by 3
Mairal, A., Tariq, U., Mehrotra, S., Matheshwaran, S., Marsal, J., & Kumar, A. (2026) · Advanced Science · doi:10.1002/advs.76585 · Cited by 3
Herbal Medicines for the Management of Irritable Bowel Syndrome and Constipation Problem
Puppala, E. R., Prasad, N., Singh, M., Prakash, A. N., Abubakar, M., Adhikari, P., & Naidu, V. G. M. (2023) · Springer eBooks · doi:10.1007/978-981-99-7703-1_16 · Cited by 5
Fan, Y., Xiao, Y., Zhang, S., Bai, W., & Chen, J. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250129 · Cited by 4
Zdanowicz, K., Pietrowska, K., Lebensztejn, D. M., Ciborowski, M., Godzień, J., Kretowski, A. J., Daniluk, J., & Daniluk, U. (2024) · Archives of Medical Science · doi:10.5114/aoms/190623 · Cited by 3
Bifidobacterial biofilms as next-generation probiotics and their role in intestinal microbiocenosis
Aziz, K., & Zaidi, A. (2024) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2024.2438119 · Cited by 5
“…effect proposed the contribution of altered gut microbiota in Git and various disease etiology (larcombe et al. 2016; Nagao-Kitamoto and Kamada 2017; Khan et al. 2019). this concept is supported by the ameliorative effect of probiotics and prebiotics treatment during intestinal bowel disorders…”
InfluentialGut Homeostasis; Microbial Cross Talks in Health and Disease Management
Khatri, G. S., Kurian, C., Anand, A., & Paari, K. A. (2021) · Current Research in Nutrition and Food Science Journal · doi:10.12944/crnfsj.9.3.28 · Cited by 3
The Role of the Human Gutome on Chronic Disease
Hoefer, C. C., Hollon, L. K., & Campbell, J. A. (2021) · Advances in Molecular Pathology · doi:10.1016/j.yamp.2021.06.003 · Cited by 3
"EFFECT OF DIETARY PROBIOTICS ON INTESTINAL MICROBIOTA IN PATIENTS WITH CROHN’S DISEASE"
Pavel, F. M., Ţiţ, D. M., Bungău, A. F., Behl, T., Tarce, A. G., & BUNGAU, S. G. (2022) · Archives of the Balkan Medical Union · doi:10.31688/abmu.2022.57.1.07 · Cited by 3
Zaker, B. S. K., Saghebjoo, M., & Islami, F. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100403 · Cited by 3
Intestinal mucosal and fecal microbiota profiles in Crohn's disease in Chinese children
Wu, P., Wu, B., Zhuang, Z., Liu, J., Hong, L., Ma, B., Lin, B., Wang, J., Lin, C., Chen, J., et al. (2022) · Medicine in Microecology · doi:10.1016/j.medmic.2022.100071 · Cited by 4
Postbiotics and their role in healthy life
Fesseha, H., Sisay, T. Y., & MEKONNEN, E. (2022) · Journal of Life Science and Biomedicine · doi:10.54203/jlsb.2022.8 · Cited by 9
“Alterations of gut microbiota sometimes collectively called “gut dysbiosis” be associated with various diseases and disorders like IBD [47], type 2 diabetes [48], depression [49], cardiovascular disease [50].”
Majumder, R., Ghosh, S., Singh, M. K., Das, A., Chowdhury, S. R., Saha, A., & Saha, R. P. (2023) · COVID · doi:10.3390/covid3040037 · Cited by 4
Aliabadi, M., Saghebjoo, M., Yakhchali, B., & Shariati, V. (2023) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2023-0071 · Cited by 4
Horseman, T. S., Rittase, W. B., Slaven, J. E., Bradfield, D. T., Frank, A. M., Anderson, J. A., Hays, E. C., Ott, A. C., Thomas, A. E., Huppmann, A. R., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084535 · Cited by 5
Fecal proteolytic profiling of pediatric inflammatory bowel disease: A pilot study
Haak, W., Jagt, J. Z., de Meij, T. G. J., Bikker, F. J., Brand, H. S., de Boer, N. K. H., & Kaman, W. E. (2024) · The FASEB Journal · doi:10.1096/fj.202302190r · Cited by 3
“19,20 IBD is associated with a dysbiosis, characterized by depletion of obligate anaerobes including Faecalibacterium prausnitzii and Roseburia hominis in CD and the enrichment of facultative anaerobes such as E. coli in UC.”
BackgroundStudy of Fecalibacteria prausntzii in Egyptian patients with inflammatory bowel disease
Atty, K. A. E., Nouh, H. H., Abdelsalam, S., Ellakany, A., Abdaalah, H., & Header, D. (2024) · Gastroenterology Review · doi:10.5114/pg.2024.139427 · Cited by 3
“…to disturbance of the equilibrium between beneficial and harmful bacteria by decreasing beneficial bacteria and increasing harmful bacteria, and it may share in the pathogenesis of a lot of diseases like IBD, irritable bowel syndrome (IBS), colon cancer, and antibiotic-associated diarrhoea [3].”
BackgroundStepanov, Y. М., Tіtova, M. V., & Tatarchuk, О. М. (2020) · GASTROENTEROLOGY · doi:10.22141/2308-2097.54.1.2020.199141 · Cited by 3
Microbial Community Analysis based on Bipartite Graph Clustering of Metabolic Network
Zhang, C., & Deng, L. (2021) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1828/1/012092 · Cited by 4
Self-citationGut Microbiota: A Future Clinical Magic Bullet to Manifest Pathogenic Disease in the Current Future
Mina, P. R. (2023) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.17.1.43 · Cited by 3
Fecal Microbial Diversity of Coyotes and Wild Hogs in Texas Panhandle, USA
Awosile, B. B., Crasto, C. J., Rahman, M. K., Daniel, I. K., Boggan, S., Steuer, A. E., & Fritzler, J. M. (2023) · Microorganisms · doi:10.3390/microorganisms11051137 · Cited by 3
Fijan, S., Connil, N., Matijašić, B. B., Sreenivasa, M. Y., & Anandharaj, M. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1720803 · Cited by 3
Functional evaluation of pure natural edible Ferment: protective function on ulcerative colitis
Chen, Y., Ye, S., Shi, J., Wang, H., Deng, G., Wang, G., Wang, S., Yuan, Q., Yang, L., & Mou, T. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1367630 · Cited by 4
Rezai, S., Ghorbani, E., Khazaei, M., Nazari, S. E., Rahmani, F., Naimi, H., Afshari, A., Avan, A., Ryzhikov, M., Soleimanpour, S., et al. (2024) · Advanced Biomedical Research · doi:10.4103/abr.abr_157_24 · Cited by 2
Chronic inflammation in case of obesity-associated diseases
Kim, O. T., Дадаева, В. А., NURULLINA, G. I., & Drapkina, O. M. (2025) · Russian Journal of Preventive Medicine · doi:10.17116/profmed202528011115 · Cited by 2
Enhancing Survival Following High-Risk Surgery by Modulating Actionable Items within the Pathobiome
Zaborina, O. Y., Zaborin, A., Keskey, R. C., & Alverdy, J. C. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1010335 · Cited by 2
Metadata
- Authors
- Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C.
- Affiliations
- Lanzhou University (CN)
- Gansu Key Laboratory of Functional Genomics and Molecular Diagnosis, Lanzhou 730000, China
- Corresponding author
- Zhang, Chunjiang
- Venue
- Pathogens
- Publisher
- MDPI AG
- Published
- 2019-08-13
- Volume
- 8
- Issue
- 3
- Pages
- 126
- ISSN
- 2076-0817 (ISSN-L)
- PMC
- PMC6789542
- OpenAlex
- W2966933380
- Cited by
- 771
- References
- 267
- Citations by year
- 2026: 43 · 2025: 105 · 2024: 149 · 2023: 134 · 2022: 135 · 2021: 132 · 2020: 66 · 2019: 7
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lanzhou University Institutional Repository (submittedVersion, cc-by-nc-sa)
- Lanzhou University Institutional Repository (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Jiangsu Science and Technology Major Project ((No. BA2016036))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- inflammatory bowel disease, gut microbiota, dysbiosis, Crohn's disease, ulcerative colitis, intestinal inflammation, microbiota-based therapy, probiotics, prebiotics, mouse colitis model, IBD pathogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.